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Abstract 
Bisphosphonates (BPs) represent the first-line treatment for a wide array of bone disorders. Despite 
their well-known action on osteoclasts, the effects they induce on osteoblasts are still unclear. In 
order to shed light on this aspect we evaluated the impact of two nitrogen containing 
bisphosphonates, Alendronate (ALN) and Zoledronate (ZOL), on human primary pre-osteoblasts. 
At first, we showed an inhibitory effect on cell viability and alkaline phosphatase activity starting 
from µM concentrations of both drugs. In addition, an inhibitory trend on mineralized nodules 
deposition was observed. Then low doses of both ALN and ZOL rapidly increased the release of the 
pro-inflammatory mediators TNFα and IL-1β, while increased DKK-1 and Sclerostin, both inhibitors 
of osteoblastogenesis. Finally, ALN and 10-7M ZOL decreased the expression of type I Collagen and 
Osteopontin, while both drugs slightly stimulated SPARC production. With these results, we would 
like to suggest a direct inhibitory action on bone-forming cells by nitrogen containing 
bisphosphonates. 
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Introduction 
Bisphosphonates (BPs) represent the elective 
therapy for several metabolic and oncological diseases 
affecting the skeletal system, such as different types of 
osteoporosis, Paget disease, osteogenesis imperfecta, 
fibrous dysplasia and primary or secondary bone 
cancer. Among nitrogen containing bisphosphonates, 
Alendronate (ALN) is mainly used for the prevention 
and treatment of osteoporosis (10mg once a day or 
70mg once a week, per os administration). Conversely, 
Zoledronate (ZOL), one of the most potent nitrogen 
containing BPs, is usually intravenously injected in 
patients with advanced malignancies to prevent 
skeletal complications, such as pathological fractures, 
cancer-induced bone loss or hypercalcemia (posology: 
4mg every 3 to 4 weeks), or in the treatment of 
osteoporosis (5mg once a year). Despite BPs’ 
well-known therapeutic potential, they also present 
important side effects. In particular, prolonged 
treatment with these drugs seems to predispose to the 
development of paradoxical side effects affecting 
bone, such as osteonecrosis of the jaw 
(Bisphosphonate Related Osteonecrosis of the Jaw, 
BRONJ) and atypical femoral fractures (AFFs) [1, 2]. 
The pathophysiology of these skeletal conditions is 
still under investigation, as their etiology seems to 
depend on the synergy of several factors [3]. For both 
side effects, drug-induced suppression of bone 
turnover, resulting in an impairment of bone quality 
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and architecture, has been identified as the starting 
cause. For BRONJ, BP anti-angiogenic action, 
inflammation, genetic predisposition and altered 
immune status are recognized among the main causes 
and favoring factors [4]. For AFFs, changes in mineral 
density and/or distribution, together with micro 
damage accumulation, are listed [3]. Recently it has 
been estimated that the frequency of BRONJ onset in 
oncology patients receiving high doses of BPs spans 
from 1 to 15%, while in osteoporosis patient its 
prevalence is not enhanced (0.001%-0.01%)[4]. Indeed, 
Zoledronate infusion for the treatment of metastatic 
bone disease is frequently associated to BRONJ 
occurrence, whereas its administration in osteoporosis 
patients has been shown to substantially reduce 
fracture risk and increase mineral apposition rate [5, 
6]. Up to now, no correlation between BP posology 
and AFFs has been described yet, but the direct 
relationship between duration of BP exposure and 
risk of developing this pathology is well 
documented [7]. 
BPs, being synthetic analogues of inorganic 
pyrophosphate, can accumulate in bone tissue and be 
incorporated into bone-resorbing cells. Depending on 
their chemical structure, they act by inhibiting 
osteoclast-mediated bone resorption. Once 
internalized into osteoclasts, non-nitrogen containing 
BPs are metabolized to non hydrolyzable ATP analogs 
that interfere with energy metabolism, whereas 
nitrogen containing BPs affect mevalonate pathway 
by preventing the prenylation of small GTPase 
signaling proteins essential for osteoclast morphology 
and function [8]. Beside this well documented 
anti-catabolic action on bone tissue, several in vitro 
evidences suggest that BPs may play a direct role in 
the process of bone formation as well. In detail, it has 
been demonstrated that BP exposure can enhance 
osteoblast differentiation, proliferation and activity 
[9-15]. In contrast, it has been suggested that µM or 
higher concentrations of BPs can inhibit 
osteoblastogenesis and induce osteoblast apoptosis 
[16-21]. The use of different experimental models and 
types of BPs, together with the employ of 
immortalized cell lines often of murine origin, might 
be responsible of these conflicting in vitro results on 
osteoblast metabolism. Therefore, we decided to 
investigate the effects of nitrogen containing BPs on 
human primary pre-osteoblasts. Herein, we show that 
high doses of both BPs exert a cytotoxic effect on 
osteoblastic cells, while lower doses affect the 
short-term release of several bone markers and 
cytokines. Moreover, we also provide evidence of a 
BP-dependent impairment of bone matrix production, 
suggesting an overall effect of these compounds on 
bone quality.  
Materials and Methods  
Reagents 
Unless otherwise stated, chemicals and reagents 
were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). 
Isolation and expansion of human primary 
pre-osteoblasts 
Bone specimens were obtained from the femoral 
head of patients subject to total hip replacement 
surgery, following the procedure approved by IRCCS 
Istituto Ortopedico Galeazzi (PQ 7.5.125, version 4). 
For each patient, personal data (age and gender) and 
medical anamnesis were collected and donors with 
history of bisphosphonate therapy, both prior and at 
the time of surgery, were excluded. For pre-osteoblast 
isolation, trabecular bone was excised from the 
mid-deep area of the femoral head, selecting 
harvesting regions distal from the lesions, then 
minced into fragments with a scalpel and washed 
with PBS (Phosphate Buffered Saline) several times in 
order to remove residual adipose and/or 
hematopoietic tissue. Between washes, samples were 
vortexed at high speed to further promote the 
removal of debris and contaminant tissues. Bone chips 
were then placed, without any step of enzymatic 
digestion [22, 23], in 60mm petri dishes and cultured 
in high glucose DMEM supplemented with 10%FBS 
(Euroclone, Pero, Italy), 2mM L-glutamine, 50U/ml 
penicillin and 50μg/ml streptomycin at 37°C in a 
humidified atmosphere containing 5% CO2. Culture 
media were changed twice a week. When cells 
outgrown from the explants reached the 90% 
confluence, they were detached and sub-cultured 
every 2 weeks. For the experiments, pre-osteoblasts 
were employed within the 3rd culture passage. The 
phenotypic characterization of osteoblastic primary 
cultures is described in Supplementary material. 
Exposure to bisphosphonates 
24 hours after seeding, pre-osteoblasts were 
exposed to several concentrations of the nitrogen 
containing BPs Alendronate (Y0001727) and 
Zoledronate (SML0223) dissolved in culture media. 
For each assay, control cells grown in the absence of 
the drugs were cultured in parallel. The wide BP 
concentration range chosen for the treatments was 
literature-based and derived from the lack of univocal 
ex vivo data on BP accumulation in bone.  
Cell viability 
3x103 cells/cm2 were seeded in triplicate on 
96-well plates. At day 1, 2, 5 and 9 pre-osteoblasts 
were treated with a wide range of ALN or ZOL 
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concentrations and cell viability was monitored 
through time as previously described [24]. Briefly, at 
each time point (day 2, 5, 9 and 12) culture media 
were replaced with 200μl DMEM supplemented with 
10%AlamarBlue® (Thermo Fisher Scientific, 
Waltham, MA, USA) and cells were incubated for 3.5 
hours at 37°C in the dark. 100µl of supernatants were 
then transferred to black bottom 96-well plates and 
fluorescence (540nm excitation λ, 600nm emission λ) 
was read with Wallac Victor II plate reader (Perkin 
Elmer, Milan, Italy).  
ALP activity assessment 
5x103 cells/cm2 were cultured in 24-wells plates 
in the presence or absence of BP concentrations 
spanning from 10-13 to 10-5M. After 14 days, cells were 
washed in PBS, lysed in 50µl 0.1%Triton X-100 and the 
protein content of each sample was quantified 
through BCA™ Protein Assay (Thermo Fisher 
Scientific, Waltham, MA, USA). Alkaline phosphatase 
enzymatic activity was assessed through a 
colorimetric assay based on the conversion of 
p-nitrophenyl phosphate (pNPP) into p-nitrophenol 
(pNP), following the procedure exhaustively 
described in [25]. The enzymatic activity (U) was 
calculated considering the amount of produced pNP 
and the reaction time, then normalized to each sample 
protein content and expressed as ALP specific activity 
(U/µg). 
Calcified extracellular matrix quantification 
5x103 cells/cm2 were cultured in 24-well plates 
either in standard conditions or in the presence of 
10-13, 10-10 or 10-7M ALN or ZOL. After 16 days, the 
deposition of calcified extracellular matrix was 
quantified following standard procedures [25]. 
Briefly,samples were fixed with 70% ethanol and 
stained with 40mM Alizarin Red-S. Specific staining 
was then extracted with 10% cetylpyridinium chloride 
in 0.1M phosphate buffer at pH 7.0 and absorbance 
was read 550nm with Wallac Victor II plate reader 
(Perkin Elmer, Milan, Italy). 
Primary cell pools 
Cell pools were obtained from three primary 
populations mixed, at the same subculture passage, 
following a 1:1:1 ratio. We produced two cell pools 
with pre-osteoblasts deriving from heterogenous 
donors, one pool deriving solely from donors younger 
than 50 y/o and one from patients older than 60 y/o. 
Details of the pools are shown in Table 1. 
Analysis of released bone biomarkers and 
cytokines  
Pooled pre-osteoblasts were seeded at a density 
of 1.5x104/cm2 and treated with 10-13, 10-10 or 10-7M 
BPs for 7 days. Conditioned media were collected at 
day 3 and 7 after treatment, centrifuged at 2000g for 5 
minutes, then stored at -20°C. The MILLIPLEX MAP 
Human Bone Magnetic Bead Panel-Bone Metabolism 
Multiplex Assay (HBNMAG-51K, Millipore, 
Burlington, MA, USA) was customized to contain 8 
key bone molecules: DKK-1, IL-6, TNFα, OPG, OPN, 
SOST, IL-1β and FGF23. Duplicates of conditioned 
media (25µl/sample) were read through Bio-Plex 
Multiplex System (Bio-Rad, Milan, Italy) following 
standard procedures. IL-6 levels were measured in 1:5 
diluted samples. Data analysis was performed with 
MAGPIX xPONENT 4.2 software (Luminex 
Corporation, Austin, TX, USA). Levels of secreted 
RANKL were determined by sandwich enzyme 
linked immunoassay (ELISA) on culture media in 
duplicate for each condition, following standard 
procedures (EK0842, Boster Bio, Pleasanton, CA, 
USA). Data were analysed with MyAssays software 
(www.myassays.com). 
Analysis of matrix production 
Cells were lysed in 65mM Tris-HCl, 2% SDS at 
pH 6.8 supplemented with protease inhibitors. 20µg 
of whole cell extracts, quantified through BCA™ 
Protein Assay (Thermo Fisher Scientific, Waltham, 
MA, USA), were resolved in SDS-PAGE and 
transferred to nitrocellulose membranes (GE 
Healthcare, Milan, Italy). Membranes were probed 
with antibodies raised against type I Collagen (#7025, 
Chondrex, Redmond, WA, USA, dilution 1:5000), 
Osteopontin (ab8448,Abcam, Hongkong, China, 
dilution 1:1000) and SPARC (sc-33645, Santa Cruz 
Biotechnology,CA, USA, dilution 1:3000). β Tubulin 
expression was also revealed (sc-9104, Santa Cruz 
Biotechnology, CA, USA, dilution 1:1000). Proteins of 
interest were detected after incubation with 
appropriate HRP-conjugated secondary antibodies 
(Santa Cruz Biotechnology, CA, USA, dilution range 
1:3000-1:5000) and revealed with LiteAblot® Turbo 
Extra-Sensitive Chemiluminescent Substrate 
(Euroclone, Pero, Italy). Images were acquired 
through ChemiDoc Imaging System™ and analysed 
through Image Lab™ software (Bio-Rad, Milan, Italy). 
Statistical analysis 
Unless otherwise stated, data are expressed as 
mean ± standard error of the mean (SEM) of at least 3 
independent experiments. Statistical analysis was 
performed by two-tailed unpaired Student´s t test 
using Prism 5 software (GraphPad Software Inc, La 
Jolla, CA, USA). Differences were considered 
significant at p≤0.05. 
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Figure 1. Influence on cell viability of repeated treatments with ALN or ZOL concentrations from 10-15 to 10-5M. Data are represented as relative values setting as 
100% the viability of untreated pre-osteoblasts at every time point (ctrl, blue dashed lines). Values are expressed as mean ± SEM of at least 3 independent experiments 
for each condition. Statistical significance versus ctrl is shown as *p<0.05 and **p<0.01. 
 
Results 
Cytotoxic effect of 10-5M ALN and ZOL on 
pre-osteoblasts 
Cell viability was monitored for 12 days of 
chronic BP treatments (concentrations up to 10-5M). 
Concentrations below µM did not affect cell viability 
(Figure 1), while repeated treatments with 10-5M ALN 
slightly decreased it starting from day 5. At day 12, a 
significant reduction of -23.2 ± 8.2% in respect to 
untreated pre-osteoblasts was observed. Differently, 
ZOL administered at the same concentration exerted a 
stronger cytotoxic action compared to ALN. A 
significant reduction of cell viability was detectable 
starting from day 5 and at the final time point it 
reached a -68.7 ± 18.3% compared to control cells. 
Moreover, metabolic and apoptotic stress were 
perceivable already at day 2, when pre-osteoblasts 
acquired a rounder shape and increased vacuole 
secretion (data not shown). All subsequent 
experiments were performed using BP concentrations 
that did not significantly affect cell viability. 
BPs influence ALP activity and calcified ECM 
deposition by pre-osteoblasts 
We investigated the effect of repeated 
administrations of ALN or ZOL on alkaline 
phosphatase (ALP) activity and calcified ECM 
production, both well-recognized markers of 
osteoblast maturation. As shown in Figure 2A, 
pre-osteoblast response to ALN stimulus was 
extremely variable at day 14, whereas for ZOL a dose 
response trend was discernible. Indeed, ZOL≤10-10M 
enhanced ALP activity of about +25% in respect to 
untreated cells, while higher concentrations 
(ZOL≥10-9M) slightly decreased it (from -11% to 
-26%). As expected, µM concentrations of both 
compounds inhibited also ALP activity (data not 
shown). Conversely, ZOL slightly inhibited 
pre-osteoblast mineralization, while 10-13 and 10-7M 
ALN reduced it to a major extent (-15.7 ± 7.7% and 
-34.9 ± 14.3% in respect to control cells, Figure 2B). 
Levels of bone biomarkers and inflammatory 
cytokines in pre-osteoblast culture medium  
Cultured human primary pre-osteoblasts 
released detectable levels of IL-6, Osteopontin (OPN), 
Sclerostin (SOST), Dickkopf-related protein 1 
(DKK-1), Osteoprotegerin (OPG), TNF-α, IL-1β and 
RANKL, while FGF-23 was undetectable (Table 2). 
Interestingly, the low basal levels of TNF-α were 
increased over time of about +94%. In addition, also 
the secretion of IL-1β was mildly upregulated, while 
the high levels of IL-6, OPN and SOST released up to 
day 3 seemed to be reduced at day 7. No variation was 
observed for DKK-1, OPG and RANKL, which 
maintained an average daily release of 548 pg/ml, 1.1 
ng/ml and 73.8 pg/ml, respectively. 
 
Table 1. Description of pre-osteoblast pools according to donor 
characteristics. OA: osteoarthritis. 
Donor characteristics Pool Culture 
passage 
Mean age 
(y/o) ± SD Gender Age (y/o) Diagnosis 
♂ 59 OA 1 3rd 56 ± 12 
♂ 66 OA 
♀ 43 Congenital Hip 
Dislocation 
♂ 64 Severe OA 2 3rd 61 ± 4 
♀ 62 Femoral Head Necrosis 
♀ 56 OA 
♂ 48 OA 3 2nd 47 ± 1 
♂ 48 OA 
♀ 46 OA 
♂ 66 Severe OA 4 2nd 66 ± 3 
♂ 69 OA 
♀ 64 OA 
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Figure 2. Effect on ALP activity and calcified ECM deposition of repeated treatments with ALN or ZOL concentrations from 10-13 to 10-7M. Data are represented 
as relative values setting as 100% the ALP activity (A) or the calcified ECM deposition (B) of untreated pre-osteoblasts (ctrl, blue dashed lines). Representative 
macrographs of Calcium nodules stained with Alizarin Red-S dye are shown. Results are expressed as mean ± SEM of at least 3 independent experiments for each 
condition. Statistical significance versus ctrl is shown as **p<0.01. 
 
Table 2. Bone biomarkers and inflammatory cytokines released 
by cultured human primary pre-osteoblasts at day 3 and 7. Data 
are expressed as mean ± SD of 4 cell pools at day 3 and 3 pools 
(pool 2-4) at day 7 (n=12 and n=9 pre-osteoblast populations 
respectively). -: non detectable. 
 secreted levels 
day 3 7 
IL-6(ng/ml) 10.7 ± 1.9 8.2 ± 1.6 
OPN(ng/ml) 3.4 ± 3.8 0.7 ± 0.1 
SOST(ng/ml) 0.36 ± 0.05 0.24 ± 0.03 
DKK-1(ng/ml) 1.9 ± 0.6 2.2 ± 0.9 
OPG(ng/ml) 3.6 ± 0.9 4.1 ± 0.2 
TNFα(pg/ml) 0.09 ± 0.02 0.21 ± 0.06 
IL-1β(pg/ml) 0.16 ± 0.02 0.22 ± 0.06 
RANKL(pg/ml) 74.6 ± 1.1 73.1 ± 0.0 
FGF-23 - - 
 
BPs influence the release of bone biomarkers 
and inflammatory cytokines by pre-osteoblasts 
At day 3, the highest doses of both ALN and 
ZOL down modulated OPN levels (Figure 3A). This 
mild reduction is maintained up today 7 just with 
10-7M ZOL, whereas 10-7M ALN treatment slightly 
enhanced OPN. The secretion of SOST, DKK-1, TNFα 
and IL-1β seemed always slightly stimulated at day 3, 
although a second BP treatment almost normalized 
their levels to untreated cells, with only 10-7M ALN 
still stimulating TNFα release at the later time point 
(Figure 3D). At day 3, RANKL levels were slightly 
down modulated and a decreased RANKL/OPG ratio 
was revealed after 10-7M ALN, 10-13 and 10-10M ZOL 
treatment (Figure 3F). In addition, OPG and IL-6 
levels were never affected by 7-day treatments (data 
not shown). In the attempt to disclose differences in 
OB response depending on donor characteristics, we 
analyzed our data considering donor age. For most 
factors, this novel analysis was irrelevant, except for 
IL-1β, whose release displayed an age-related trend in 
response to BP administration (Figure 4). In fact, at 
day 3 all ALN concentrations stimulated pre- 
osteoblasts isolated from donors younger than 50 y/o 
to secrete IL-1β and a similar trend was observed after 
ZOL administration. On the contrary, cells harvested 
from older patients were not affected (data not 
shown). Unexpectedly, at day 7 both compounds 
reduced IL-1β release by cells derived from young 
donors (Figure 4), while cells harvested from elderly 
patients were either unaffected or slightly stimulated 
by the highest concentrations (data not shown).  
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Figure 3. BP effect on protein secretion by pooled human primary pre-osteoblasts. OPN (A) SOST(B) DKK-1 (C) TNFα (D) IL-1β (E) RANKL and OPG (F) release 
was evaluated at both day 3 and 7 after ALN or ZOL treatment. Data are represented as relative values setting as 100% the secretion levels of the different analytes 
by untreated pre-osteoblasts (ctrl, blue dashed lines). Values are expressed as mean ± SEM of 4 (pool 1-4) and 3 (pool 2-4) independent experiments at each time 
point (n=12 and n=9 cell populations respectively). For each pool, donor characteristics are described in Table 1. Statistical significance versus ctrl is shown as 
*p<0.05. 
 
 
Figure 4. IL-1β secretion by pooled human primary pre-osteoblasts deriving from donors younger than 50 years old (pool 3, donor characteristics are described in 
Table 1). IL-1β secretion was evaluated at day 3 and 7 after treatment with ALN and ZOL. Data derive from 3 osteoblastic populations and are expressed as mean 
± SD of technical replicates. 
 
BPs impair the expression of ECM proteins by 
pre-osteoblasts 
Most concentrations of ALN seemed to reduce 
both COLL I and OPN expression, whereas only the 
highest one significantly enhanced SPARC 
production (+19.6 ± 5.8% in respect to control cells). 
Differently, 10-7M ZOL seemed to reduce OPN and 
COLL I expression (mean decrease of -15 and -28%, 
respectively), but all doses favored SPARC increase 
(higher than +70% for 10-13 and 10-10M, around +34% 
for 10-7M). 
Int. J. Med. Sci. 2019, Vol. 16 
 
 
http://www.medsci.org 
29 
 
Figure 5. Protein expression by pooled primary human pre-osteoblasts after 7 days of BP treatment. (A) Representative blot with specific bands for COLL I, OPN, 
SPARC and β Tubulin expression. (B) Densitometric evaluation of the expression of ECM proteins by pre-osteoblasts. β Tubulin was used as internal control and 
each analyte was normalized on it. Data are expressed as relative values setting as 100% the expression of COLL I, OPN or SPARC by untreated pre-osteoblasts (ctrl, 
blue dashed lines). Results are represented as mean ± SEM of 3 independent experiments (pool 1, 2 and 4) and are obtained from 9 osteoblastic populations. For each 
pool, donor characteristics are described in Table 1. Statistical significance versus ctrl is shown as *p<0.05. 
 
Discussion 
Although it is widely accepted that the 
pharmacological mechanism of action of BPs mainly 
relies on the inhibition of osteoclasts, recent evidences 
suggest that they might directly interfere with 
osteoblasts, the anabolic counterpart of bone 
turnover. The process through which BPs are 
internalized by osteoclasts during the resorptive 
phase of bone remodeling cycle has been completely 
unravelled [26], whereas little is known about their 
incorporation mechanism into non-resorbing cells. In 
2008 Coxon et al. were the first to describe the 
different responses to soluble or mineral-bound BPs 
by both resorbing and non-resorbing cells. The 
authors demonstrated that macrophages and 
osteoblasts grown in monocultures could internalize 
only limited amounts of drugs from the mineralized 
matrix. On the contrary, when cells were co-cultured 
with osteoclasts, the internalization rate was higher, 
indicating that the release of these molecules from the 
calcified matrix mediated by osteoclasts can affect 
neighboring targets [27]. 
Here we show that high concentrations of both 
tested drugs strongly reduce pre-osteoblast viability. 
Moreover, also alkaline phosphatase activity is 
decreased by µM doses of BPs (data not show) and 
10-7M ZOL, while low concentrations of ZOL slightly 
increased it. These data corroborate with the 
hypothesis of a dual nature of BP action on cells 
belonging to the osteoblastic lineage depending on 
dosage, recently resumed by Maruotti et al.: an 
inhibition at concentrations higher than µM and a 
stimulation at lower doses [28]. However, the 
pro-osteoblastic/bone-sustaining effect by low BP 
doses described in literature [29, 30], that we observed 
on ALP activity, in our experimental set up is 
disproved by analyzing a more mature marker of 
osteogenesis, the mineralization capacity. Indeed, we 
gave evidence of an inhibitory trend affecting 
pre-osteoblast mineralization potential following 
treatments with both drugs, with ALN exerting a 
stronger effect. 
Since in our hands BPs directly affect 
metabolism and function of bone-forming cells, we 
investigated their influence on the release of soluble 
mediators involved in cell-cell crosstalk within bone 
milieu. In order to minimize the donor-related 
variability, we applied a cell pooling strategy, an 
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approach quite convenient when working with 
human primary populations [31, 32]. We are aware 
that despite this set up allowing reduced variability 
both within and between experiments, its major 
disadvantage, beside a diminished statistical power, is 
the loss of information on the behavior of each 
individual population [33]. In any case, we believe 
that data obtained following this approach minimize 
the impact on the cumulative result of any eventual 
experimental serendipity or bias. 
We gave evidence of a short-term 
pro-inflammatory and an anti-osteoanabolic effect of 
ALN and ZOL treatment. In detail, after a single 
administration of both BPs we observed a positive 
trend in the secretion of TNFα and IL-1β, classically 
known to inhibit osteoblast differentiation and 
stimulate bone resorption [34, 35]. This 
pro-inflammatory phenotype within the bone 
microenvironment can be interpreted as a positive 
stimulus to early phase osteogenesis, as in 
physiological conditions bone regeneration and 
healing are triggered by the onset of an injury-derived 
inflammatory reaction [36, 37]. In this perspective, the 
enhanced early secretion of IL-1β by cells deriving 
from young patients could fit the physio-pathological 
context of BP-related skeletal side effects. Indeed, it is 
well documented that age represents one of the major 
risk factors associated to BRONJ onset [38]. Our data 
agree with previous in vitro [39] and ex vivo [40, 41] 
studies that described a correlation between 
inflammation and nitrogen containing BPs. Here we 
are the first to show a direct pro-inflammatory action 
on pre-osteoblasts, since previously it was 
investigated on immune cells, mainly macrophages 
[39, 42, 43]. Furthermore, BPs increased the early 
release of SOST and DKK-1, known inhibitors of 
osteoblastogenesis acting on Wnt/β catenin pathway 
[44]. Interestingly, RANKL/OPG ratio was slightly 
down modulated by the rapid BP treatment, in 
contrast to OPG and RANKL levels that were not 
significantly affected (data not shown). As RANKL 
promotes osteoclast differentiation and OPG being its 
decoy receptor, their decreased ratio suggests an 
inhibitory influence on osteoclastogenesis and 
osteoclast differentiation. Conversely, in agreement 
with the hypothesis of a BP-dependent anti-anabolic 
effect on bone, in treated cells the early secretion of 
Osteopontin was reduced and a modulation of several 
intracellular ECM proteins was observed. Indeed, 
both ALN and 10-7M ZOL slightly inhibited type I 
Collagen and Osteopontin expression, whereas the 
production of SPARC seemed to be enhanced, 
suggesting a drug-dependent modification affecting 
the quality of the osteoid. In contrast to our results on 
cell viability and ALP activity, the more potent 
influence by ALN on the release and/or production of 
COLL I and OPN raises additional questions on BP 
mechanism of action. Beside a diverse internalization 
rate, we suggest that these compounds might interfere 
on distinct molecular pathways and this aspect will 
require further investigations. With the perspective of 
unraveling a direct BP effect on OBs that may explain 
BRONJ onset, Manzano-Moreno et al. performed 
short ALN and ZOL treatments on human primary 
osteoblasts and MG-63 osteosarcoma cell line to 
evaluate the gene expression of several osteoblast 
biomarkers [45]. They showed an inhibition of type I 
Collagen and ALP that partly agrees with our results. 
Indeed, they found that 10-7M ALN is more potent 
than ZOL in downregulating COLL I mRNA levels. 
Moreover, a decreased ALP gene expression in 
agreement with our reduced activity was observed 
with µM BP concentrations. Finally, also the lack of 
modulation of OPG by low BP doses collimates with 
our data on protein release. Interestingly, they 
described an increase of OPG mRNA levels in treated 
MG-63 cells that highlights the possibility of 
inconsistent results among primary cells and cell 
lines.  
Taken together, our data show that low BP doses 
act directly on bone-forming cells by increasing the 
expression of negative bone mediators and impairing 
ECM quality, suggesting an overall anti-anabolic 
effect on bone milieu. We believe that the unbalance 
of bone microarchitecture and cell-cell crosstalk might 
be related to the development of the drug-related side 
effects often described at the skeletal level. 
Conclusions 
Based on our in vitro results, we hypothesize that 
BPs may exert an anti-anabolic action within bone 
microenvironment that could be partially involved in 
the development of side effects affecting the skeletal 
system, such as BRONJ or AFFs. We would like to 
propose that, when osteoblasts are exposed to BPs in 
pre-pathological conditions, their rapid response may 
determine an unbalance of the remodelling cycle that, 
in synergy with other predisposing factors (e.g. bone 
microdamage, inflammation) and drug-dependent 
effects (e.g. soft tissue toxicity, inhibition of 
angiogenesis), may concur to the pathology onset. 
Supplementary Material  
Supplementary method and figure.  
http://www.medsci.org/v16p0023s1.pdf  
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